The news is getting out about the upside potential here.
Company has no debt, low float, number of short shares is a high percentage of the low float, a number of potential suitors in the acquisition mode, a new BOD member with thirty years of experience in international acquisitions with Merrill Lynch, and a PDUFA date for its revoutionary insulin drug/delivery system fast approaching in October with no advisory panel.
It's no wonder the option sentiment is so "bullish".
$10.00 before the PDUFA date and $20-$25 on approval.
p.s. Buy a few share before more positive news is out.
Being one of the highest percentage gainers on the NASDAQ also helps.
The recent focus on companies that have FDA decisions impacting them will also bring new buyers to Biodel.
The fact that big pharma is now focusing on acquiring technology and new drugs via the acquisition route is also a very positive factor here considering how undervalued Biodel is compared to other companies with products in the pipeline.
This has to be one of the best opportunities in the market for appreciation leading to next month's approval.